11 – 12/06/2021

Despite COVID-19 pandemic predicaments, IASIS PHARMA successfully participated in the Annual Spring Day Hybrid (both with physical and in webinar form) Conference, held by the Hellenic Society of Dermatology and Venereology, which took place on June 11 – 12 at Athens Concert Hall – International Conference Centre.

IASIS PHARMA participated actively in the event, once more proving its strong interest in the field of Dermatology and Venereology. At IASIS PHARMA exhibition stand, two of its major dermatological products were exhibited: Modiwart® and Combi®.

– Modiwart®, with imiquimod as its active ingredient, is an innovative immunomodulator, with the following indications:
-external genital and anogenital warts (condyloma acuminata) in adults.
-small superficial basal cell carcinomas (sBCCs)
-clinically typical actinic keratosis.
Modiwart® is available as a cream (5%) for topical use, in single-use sachets (12 per package).

– Combi® is a miconazole + fluprednidene combination in the form of cream, having excellent texture and the advantage of 50g per package.